Pharos I Bio Joins Lilly's AI Drug Discovery Platform

Proprietary AI Platform 'Chemiverse'
Connected to Lilly's AI and Big Data Infrastructure

Pharos I Bio, an artificial intelligence (AI) drug discovery company, announced on June 9 that it has signed an agreement to join the AI drug discovery platform 'Lilly Tunelab' operated by global pharmaceutical firm Eli Lilly.

From the left, logos of Pharos iBio and Lilly TuneLab companies. Pharos iBio

Lilly Tunelab is an AI and machine learning (ML) collaboration program within 'Catalyze360,' Eli Lilly's open innovation platform. Based on federated learning technology, it is designed to allow pharmaceutical and biotech companies to participate in developing AI models without disclosing their data externally.

Pharos I Bio plans to leverage its accumulated experience in candidate discovery and clinical development, gained through its proprietary AI drug discovery platform Chemiverse, and connect this expertise to Eli Lilly’s AI and ML drug development environment. The company will review the physicochemical properties, druggability, and development potential of its key pipelines through this collaboration.

The company expects that this partnership will reduce the costs associated with securing large-scale data and AI infrastructure, while also verifying the global competitiveness of its Chemiverse-based candidates and development strategies. Moving forward, Pharos I Bio aims to pursue joint research and technology commercialization opportunities with global pharmaceutical companies, building upon its collaboration with Eli Lilly.

A representative from Pharos I Bio commented, “This marks the starting point for linking our expertise in candidate discovery and clinical development, accumulated through Chemiverse, with the AI and ML collaboration framework of global big pharma. We will continue to expand opportunities for global AI drug discovery collaborations.”

This content was produced with the assistance of AI translation services.